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IBD is composed of chronic, relapsing intestinal inflammatory dis-
eases affecting more than 2.5 million people in Europe, with increasing 
prevalence in Asia and developing countries1,2. IBD is thought to arise 
from inappropriate activation of the intestinal mucosal immune system 
in response to commensal bacteria in a genetically susceptible host.
Thus far, 163 genetic loci have been associated with IBD via large-
scale genome-wide association studies (GWAS) in cohorts of European 
descent. Smaller GWAS performed in populations from Japan, India 
and Korea have reported six new genome-wide significant associations 
outside of the human leukocyte antigen (HLA) region. Three of these 
loci (13q12, FCGR2A and SLC26A3) subsequently achieved genome-
wide significant evidence of association in European cohorts. The 
remaining three loci demonstrated a consistent direction of effect 
and nominally significant evidence of association (P < 1 × 10−4) in 
previous European GWAS analyses3–6. A number of loci initially asso-
ciated with IBD in European cohorts have now also been shown to 
underlie risk in non-Europeans, including JAK2, IL23R and NKX2-3. 
The evidence of shared IBD risk loci across diverse populations 
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suggests that combining genotype data from cohorts of different 
ancestry will enable the detection of additional IBD-associated loci. 
Such trans-ancestry association studies have successfully identi-
fied susceptibility loci for other complex diseases, including type 2 
diabetes and rheumatoid arthritis7,8.
In this study, we aggregate genome-wide or Immunochip genotype 
data from 96,486 individuals. In comparison to our previously 
published GWAS meta-analysis, this study includes an additional 
11,535 individuals of European ancestry and 9,846 individuals of 
non-European ancestry. Using these data, we aim to identify new IBD 
risk loci and compare the genetic architecture of IBD susceptibility 
across ancestrally divergent populations.
RESULTS
Study design
After quality control and 1000 Genomes Project imputation (Phase I– 
August 2012), we used 5,956 Crohn’s disease cases, 6,968 ulcerative 
colitis cases and 21,770 population controls of European descent to 
perform GWAS of Crohn’s disease, ulcerative colitis and IBD (Crohn’s 
disease and ulcerative colitis together) (Online Methods). Replication 
was undertaken using an additional 16,619 Crohn’s disease cases, 13,449 
ulcerative colitis cases and 31,766 population controls genotyped 
on the Immunochip. The replication cohort included 2,025 Crohn’s 
disease cases, 2,770 ulcerative colitis cases and 5,051 population 
controls of non-European ancestry (Table 1 and Supplementary 
Figs. 1 and 2), so principal-component analysis was used to assign 
individuals to 1 of 4 ancestral groups (European, Iranian, Indian or 
East Asian) (Supplementary Fig. 3). Case-control association tests 
were performed within each ancestry group using a linear mixed 
model (MMM)9 (Online Methods). A fixed-effects meta-analysis was 
undertaken to combine the summary statistics from our European-
only GWAS meta-analysis with those from the European replication 
cohort. We next performed a Bayesian trans-ancestry meta-analysis, 
as implemented in MANTRA, to enable heterogeneity in effect sizes 
to be correlated with the genetic distance between populations, as 
estimated by the mean fixation index (FST) across all SNPs10 (Online 
Methods). For the trans-ancestry meta-analysis, the 6,392 cases and 
7,262 population controls of European ancestry that were present 
in both the GWAS and replication cohorts were excluded from the 
Immunochip replication study (Supplementary Fig. 2). To maximize 
power for our solely Immunochip-based comparisons across ances-
tral groups, the mixed-model association analysis was repeated after 
reinstating these individuals in the Immunochip cohort.
Trans-ancestry meta-analysis identifies 38 new IBD loci
In total, 38 new disease-associated loci were identified at genome-
wide significance in either the association analysis of individual 
ancestry groups (P < 5 × 10−8) or the trans-ancestry meta-analysis that 
included all ancestries (log10(Bayes factor) > 6) for ulcerative colitis, 
Crohn’s disease or IBD (Table 2, Supplementary Figs. 4–7 and 
Supplementary Tables 1 and 2). To reduce false positive associations, 
we required all loci only implicated in disease risk via the trans-
ancestry meta-analysis (with log10(Bayes factor) > 6 but P > 5 × 10−8 
in each individual ancestry cohort) to show no significant evi-
dence of heterogeneity across all four ancestry groups (I2 > 85.7%) 
(Online Methods and Supplementary Table 3).
Twenty-five of the 38 newly associated loci overlapped with loci 
previously reported for other traits, including immune-mediated 
diseases, whereas 13 had not previously been associated with any 
disease or trait (Online Methods and Supplementary Table 4). 
A likelihood-modeling approach showed that 27 of the 38 newly 
identified loci were associated with both Crohn’s disease and ulcera-
tive colitis (designated here as IBD-associated loci), with 7 of these 
loci demonstrating evidence of heterogeneity of effect between the 2 
diseases. Of the remaining 11 loci, 7 were classified as specific to 
Crohn’s disease and 4 were classified as specific to ulcerative colitis 
(Table 2 and Supplementary Table 1).
As a result of our updated sample quality control procedure, 17 of 
the 194 independent SNPs reported at genome-wide significance in 
our previous European-only GWAS meta-analysis6 failed to reach this 
significance threshold in the present study. Sixteen of these loci still 
demonstrated strong suggestive evidence of association in the current 
European cohort (5 × 10−8 < P < 8.7 × 10−6, representing a false discov-
ery rate (FDR) of ~0.001) (Supplementary Table 1). SNP rs2226628 on 
chromosome 11 failed to achieve even suggestive evidence of associa-
tion in our current European association analysis (P = 0.0024). Our pre-
vious European-only meta-analysis incorporated a number of principal 
components as covariates in a logistic regression test of association, 
and, interestingly, if we adopted the approach taken by Jostins et al.6, 
we observed a more significant P value of 7.38 × 10−6 for this SNP. 
This observation, together with the divergent allele frequencies at this 
SNP across European populations (1000 Genomes Project release 14: 
GBR (British in England and Scotland), 0.20; CEU (Utah residents of 
Western European ancestry), 0.28; IBS (Spanish Iberian), 0.39; FIN 
(Finnish), 0.47) suggests that the previously reported signal of associa-
tion might have been driven, at least in part, by population stratification 
(which is now better accounted for in the linear mixed-model analy-
sis)6. In summary, we now consider 231 independent SNPs within 
200 loci to be associated with IBD risk (Supplementary Table 2).
Forty-one of the 163 IBD-associated SNPs originally identified in 
our previous European-only GWAS meta-analysis replicated in at least 
one non-European cohort if we considered a one-tailed Bonferroni-
corrected significance threshold of P < 6.1 × 10−4 (0.05/163) 
(Supplementary Table 1). Nine of the 14 non-HLA loci (10 for 
Crohn’s disease and 4 for ulcerative colitis) that had been identified at 
genome-wide levels of significance in previous non-European GWAS 
cohorts from Japan, India and Korea3,4,11–13 were associated with 
either Crohn’s disease or ulcerative colitis in the East Asian, Indian 
and/or Iranian cohorts with P < 1.0 × 10−5 (Supplementary Table 5). 
Four of the five remaining SNPs (or reliable proxy SNPs) were not 
present on the Immunochip. The previously reported association 
at rs2108225 (SLC26A3) on chromosome 7 showed an association sig-
nal at P = 2.64 × 10−3 in the current East Asian cohort but was strongly 
associated with IBD in the European cohort (P = 1.04 × 10−18).
We next performed a series of analyses to prioritize genes within 
the newly associated loci for causality. Cis-eQTL (expression quantita-
tive trait locus) analysis from two data sets of peripheral blood sam-
ples from a total of 1,240 individuals showed that 12 of the 38 newly 
associated SNPs had cis-eQTL effects (FDR < 0.05) (Online Methods 
and Supplementary Table 6). Two SNPs showed trans-eQTL effects. 
table 1 cohort sample sizes for GWAS and immunochip  
trans-ancestry meta-analysis
Population Crohn’s disease Ulcerative colitis IBD
Cases Controls Cases Controls Cases Controls
European  
GWAS
5,956 14,927 6,968 20,464 12,882 21,770
European  
Immunochip
14,594 26,715 10,679 26,715 25,273 26,715
Non-European  
Immunochip
2,025 5,051 2,770 5,051 4,795 5,051
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SNP rs653178 in a locus harboring SH2B3 and ATXN2 is associated 
with multiple other immune-mediated diseases, including celiac dis-
ease and rheumatoid arthritis. It had trans-eQTL effects on 14 genes, 
including genes within IBD-associated loci (TAGAP and STAT1). 
rs616597 had a cis-eQTL effect on NFKBIZ and had trans-eQTL 
effects on FLXB13 (Supplementary Table 6) (ref. 14). Both SNPs 
reside in known DNase I hypersensitivity and histone modification 
sites in multiple cell lines (Supplementary Table 7). In contrast to 
the high number of SNPs tagging eQTLs, only 3 of the 38 SNPs were 
in high linkage disequilibrium (LD; r2 > 0.8) with known missense 
coding variants (Supplementary Table 8).
To enable a meaningful comparison with our previously published 
results, we recreated the GRAIL connectivity network using all loci 
that now achieved genome-wide significant evidence of association 
(Supplementary Fig. 8). Twelve genes in the previous GRAIL network 
were removed in this new network. We found that these genes had 
significantly larger GRAIL P values (Wilcoxon P value = 6 × 10−4) and 
fewer interaction partners (11.2 versus 16.0) than genes remaining in 
the network. Sixty-two genes were connected into the GRAIL network 
for the first time, only 36 of which were located within the newly 
associated loci (including NFKBIZ, CD28 and OSMR). Thus, 26 genes 
from previously established IBD loci are brought into the network 
table 2 Newly associated iBD risk loci








factor)d Het. (I2)e European OR European P Candidate gene(s)
 1 rs1748195 63,049,593 G CD CD 6.08 0 1.07 (1.04–1.10) 7.13 × 10−8 USP1
 1 rs34856868 92,554,283 A IBD IBD_U 6.16 0 0.82 (0.77–0.88) 9.80 × 10−9 BTBD8
 1 rs11583043 101,466,054 A UC IBD_U 8.34 66.5 1.08 (1.05–1.11) 6.05 × 10−8 SLC30A, EDG1
 1 rs6025 169,519,049 A IBD IBD_U 6.43 0 0.84 (0.79–0.89) 2.51 × 10−8 SELP, SELE, SELL
 1 rs10798069 186,875,459 A CD IBD_S 7.24 0 0.93 (0.91–0.95) 4.25 × 10−9 PTGS2, PLA2G4A
 1 rs7555082 198,598,663 A CD IBD_U 7.97 0 1.13 (1.09–1.17) 1.47 × 10−10 PTPRC
 2 rs11681525 145,492,382 C CD CD 8.8 59.3 0.86 (0.82–0.90) 4.08 × 10−11 –
 2 rs4664304 160,794,008 A IBD IBD_U 6.34 0 1.06 (1.04–1.08) 2.61 × 10−8 MARCH7, LY75, PLA2R1
 2 rs3116494 204,592,021 G UC IBD_S 7.03 0 1.08 (1.05–1.11) 1.30 × 10−7 ICOS, CD28, CTLA4
 2 rs111781203 228,660,112 G IBD IBD_U 10.04 0 0.94 (0.92–0.96) 2.16 × 10−10 CCL20
 2 rs35320439 242,737,341 G CD IBD_S 7.71 0 1.09 (1.06–1.12) 9.89 × 10−10 PDCD1, ATG4B
 3 rs113010081 46,457,412 G UC IBD_U 7.45 0 1.14 (1.09–1.19) 9.02 × 10−10 FLJ78302, LTF, CCR1, 
CCR2, CCR3, CCR5
 3 rs616597 101,569,726 A UC UC 6.68 54.7 0.93 (0.90–0.96) 9.34 × 10−6 NFKBIZ
 3 rs724016 141,105,570 G CD CD 7.41 70.9 1.06 (1.04–1.09) 3.36 × 10−6 –
 4 rs2073505 3,444,503 A IBD IBD_U 6.87 0 1.10 (1.06–1.14) 1.46 × 10−7 HGFAC
 4 rs4692386 26,132,361 A IBD IBD_U 6.47 0 0.94 (0.92–0.96) 1.21 × 10−8 –
 4 rs6856616 38,325,036 G IBD IBD_U 9.78 61.6 1.10 (1.06–1.14) 9.72 × 10−7 –
 4 rs2189234 106,075,498 A UC UC 8.85 0 1.08 (1.05–1.11) 1.95 × 10−10 –
 5 rs395157 38,867,732 A IBD IBD_U 19.5 0 1.10 (1.08–1.12) 2.22 × 10−20 OSMR, FYB, LIFR
 5 rs4703855 71,693,899 A IBD IBD_U 6.83 70.3 0.93 (0.91–0.95) 7.16 × 10−11 –
 5 rs564349 172,324,978 G IBD IBD_U 8.12 37.5 1.06 (1.04–1.08) 1.54 × 10−7 C5orf4, DUSP1
 6 rs7773324 382,559 G CD IBD_U 7.67 0 0.92 (0.90–0.94) 1.06 × 10−9 IRF4, DUSP22
 6 rs13204048 3,420,406 G CD IBD_S 7.23 53.5 0.93 (0.91–0.95) 2.89 × 10−8 –
 6 rs7758080 149,577,079 G CD IBD_S 7.88 0 1.08 (1.05–1.11) 7.27 × 10−9 MAP3K7IP2
 7 rs1077773 17,442,679 G UC UC 5.86 76.7 0.93 (0.91–0.95) 5.96 × 10−9 AHR
 7 rs2538470 148,220,448 A IBD IBD_U 10.93 54.6 1.07 (1.05–1.09) 3.00 × 10−11 CNTNAP2
 8 rs17057051 27,227,554 G IBD IBD_U 6.74 15.9 0.94 (0.92–0.96) 5.50 × 10−8 PTK2B, TRIM35, EPHX2
 8 rs7011507 49,129,242 A UC IBD_U 7.49 39.3 0.90 (0.87–0.93) 6.40 × 10−8 –
10 rs3740415 104,232,716 G IBD IBD_U 6.26 0 0.95 (0.93–0.97) 1.03 × 10−7 NFKB2, TRIM8, TMEM180
12 rs7954567 6,491,125 A CD CD 8.25 0 1.09 (1.06–1.12) 1.30 × 10−9 CD27, TNFRSF1A, LTBR
12 rs653178 112,007,756 G IBD IBD_U 6.57 49.7 1.06 (1.04–1.08) 1.11 × 10−8 SH2B3, ALDH2, ATXN2
12 rs11064881 120,146,925 A IBD IBD_U 7.02 31.7 1.10 (1.06–1.14) 5.95 × 10−8 PRKAB1
13 rs9525625 43,018,030 A CD CD 8.55 37.3 1.08 (1.05–1.11) 1.41 × 10−9 AKAP1, TFSF11
17 rs3853824 54,880,993 A CD IBD_S 8.46 50.4 0.92 (0.90–0.94) 1.17 × 10−10 –
17 rs17736589 76,737,118 G UC UC 6.53 53.4 1.09 (1.06–1.12) 4.34 × 10−8 –
18 rs9319943 56,879,827 G CD CD 6.33 33.4 1.08 (1.05–1.11) 9.05 × 10−7 –
18 rs7236492 77,220,616 A CD IBD_S 6.6 0 0.91 (0.88–0.94) 9.09 × 10−9 NFATC1, TST
22 rs727563 41,867,377 G CD CD 7.1 76 1.10 (1.07–1.13) 1.88 × 10−10 TEF, NHP2L1, PMM1, 
L3MBTL2, CHADL
Loci for IBD, ulcerative colitis or Crohn’s disease were identified through a trans-ancestry analysis of genome-wide and Immunochip genotype data from a cohort of 86,682  
European individuals and 9,846 individuals of non-European descent. Loci achieving genome-wide significance (P < 5 × 10−8) in one of the individual cohorts of European,  
East Asian, Indian or Iranian descent or log10 (Bayes factor) > 6 in the combined trans-ancestry association analysis were considered to be significantly associated loci. Loci having 
log10 (Bayes factor) > 6 but P > 5 × 10−8 in each individual ancestral cohort were required to show no significant evidence of heterogeneity across all four ancestry groups  
(I2 > 85.7%). Association P values and odds ratios for the non-European cohorts are given in Supplementary table 1. Candidate genes were identified by at least one of the  
gene prioritization methods we performed (eQTL, GRAIL, DAPPLE and coding SNP annotation (cSNP); see the main text and Online Methods). Genes in bold were prioritized  
by >2 gene prioritization strategies. UC, ulcerative colitis; CD, Crohn’s disease; IBD, inflammatory bowel disease; chr., chromosome; OR, odds ratio.
aThe minor allele in the European cohort was chosen to be the reference allele. bPhenotype with the largest MANTRA Bayes factor. cThe preferred phenotype (ulcerative colitis, Crohn’s disease  
or IBD) from our likelihood-modeling approach classifying loci according to their relative strength of association. LR, likelihood ratio. IBD_S and IBD_U refer to the IBD saturated and IBD 
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of the T cell response. Thus, beyond the involvement of type 17 helper 
T (TH17) cells (previously identified through associations with, for 
example, IL23R), our results now implicate all three components of 
T cell activation (TCR ligation, co-stimulation and interleukin (IL)-2 
signaling). Notably, these processes are critical for the development 
of immunological memory and are common to both CD4+ and 
CD8+ T cells.
The functions of leading new positional candidate genes are 
discussed in Box 1.
Comparing non-European IBD with European IBD
Recent large-scale trans-ancestry genetic studies of complex diseases 
have shown that the majority of risk-associated loci are shared across 
divergent populations8,17,18. The true extent of sharing is difficult 
to characterize because the sizes of non-European cohorts are often 
much smaller than their European counterparts, limiting power to 
detect associated loci. Despite our study including a large cohort of 
9,846 non-European samples and being the largest non-European 
study of IBD thus far, this sample size is still small in comparison 
with the European cohort of 86,640 individuals. As such, we expect 
that the majority of known risk loci will not be associated in the non-
European populations at genome-wide significance. Nevertheless, we 
observed a striking positive correlation in the direction of effect when 
comparing the 231 independently associated SNPs in the European 
and East Asian cohorts (P < 1.0 × 10−22 for Crohn’s disease and 
P < 1.0 × 10−31 for ulcerative colitis) (Fig. 1). Furthermore, of 3,900 
suggestively associated SNPs (5 × 10−5 ≤ P < 5 × 10−8) from the 
European-only IBD association analysis, 2,566 had the same direction 
of effect in the East Asian analysis (P = 5.92 × 10−88). Consistent with 
for the first time, 12 of which are the only GRAIL gene reported for 
the corresponding locus, including TAGAP and IKZF1. Genes within 
the 16 previously associated loci that failed to reach genome-wide 
significance in our current study had similar average connectivities 
as other genes in the network (17.8 versus 16.4, respectively; Wilcoxon 
P value = 0.94), thus further supporting their likely involvement in 
IBD risk. Thirty-seven of 56 DAPPLE candidate genes were identified 
as candidates in the GRAIL analysis (Supplementary Table 9).
Biological implications of newly associated IBD loci
Previous GWAS analyses have highlighted components in several key 
pathways underlying IBD susceptibility, many involved in innate immu-
nity, T cell signaling and epithelial barrier function. Accepting the need 
for fine mapping to pinpoint causal variants within the newly identified 
loci, the current study expands the range of pathways implicated.
The process of autophagy, which is an intracellular process during 
which cytoplasmic content is engulfed by double-membrane autophago-
somes and delivered to the vacuole or lysosome for degradation and 
recycling, has been implicated in Crohn’s disease pathogenesis since the 
identification of ATG16L1 and IRGM as Crohn’s disease susceptibility 
genes15. The newly identified Crohn’s disease gene ATG4B encodes a 
cysteine protease with a central role in this process, reinforcing the 
importance of autophagy in Crohn’s disease pathogenesis. Likewise, 
the importance of epithelial barrier function in IBD pathogenesis 
(previously highlighted by associations with LAMB1 and HNF4A16) 
is underscored by the new association at OSMR, which modulates a 
barrier-protective host response in intestinal inflammation.
Many of the newly identified candidate genes, including LY75, 
CD28, CCL20, NFKBIZ, AHR and NFATC1, modulate specific aspects 
Box 1 Select candidate genes in the newly associated iBD susceptibility loci 
PTGS2 encodes COX-2, an enzyme that converts arachidonic acid into prostaglandins and that is the pharmacological target of non-steroidal anti-inflammatory 
drugs (NSAIDs). Prostaglandins were once thought to be exclusively proinflammatory (hence the anti-inflammatory moniker of NSAIDs), although there is now 
increasing evidence that some may have important anti-inflammatory roles through inhibiting T cell activation and promoting regulatory T cell development25. 
Consistent with this new evidence, NSAIDs are generally avoided in IBD, as they are known to precipitate disease flares.
LY75 encodes DEC-205 (also known as CD205), a cell surface receptor that is highly expressed on dendritic cells and is involved in the endocytosis of  
extracellular antigens and their presentation on major histocompatibility complex (MHC) class I molecules26. This receptor has been shown to have an important 
role in T cell function and homeostasis27.
CD28 encodes a key co-stimulatory molecule that has an important role in T cell activation. The corresponding locus contains other genes that are also involved 
in T cell co-stimulation, including ICOS and CTLA4. Stimulation of T cells in the absence of co-stimulatory signal typically leads to anergy—one of the three 
main processes that can bring about tolerance, an important means of preventing aberrant immunological responses to intestinal antigens.
CCL20 encodes a chemokine that is produced by the intestinal epithelium28 and that binds and activates CCR6. This interaction is important in regulating the 
migration of T cells (especially regulatory T cells) and dendritic cells to the gut, with increased production of CCL20 being detectable during inflammation29. 
Consistent with this evidence, IBD in mouse models is modulated by the absence of CCR6 (ref. 30). The CCR6 locus is itself associated with IBD.
NFKBIZ encodes NF-κB inhibitor ζ (NFKBIZ), an inducible regulator of NF-κB. This protein has been shown to have several functions, including roles in natural 
killer cell activation31 and monocyte recruitment32. Recently, however, NFKBIZ has also been shown to be a critical regulator of TH17 cell development through 
its interaction with ROR nuclear receptors33. Accordingly, this association further underlines the importance of TH17 cells in IBD pathogenesis.
OSMR encodes the oncostatin M receptor, a cytokine receptor component that heterodimerizes with other proteins to form both the oncostatin M receptor and 
the IL-31 receptor. Oncostatin M is present at elevated levels in biopsies from patients with active IBD and is thought to promote intestinal epithelial cell  
proliferation and wound healing, thereby augmenting the barrier function of the intestinal epithelium in intestinal inflammation16.
AHR encodes the aryl hydrocarbon receptor, a ligand-activated transcription factor that can bind to a range of aromatic hydrocarbons, including several  
compounds derived from dietary components. This receptor is highly expressed on TH17 cells, and its ligation leads to their expansion and enhanced  
production of cytokines, including IL-22 (ref. 34). Moreover, deficiency of this receptor (or its ligands) also disrupts intraepithelial lymphocyte homeostasis,  
leading to failure to control intestinal microbial load and composition and aberrant immune activation resulting in epithelial damage35. Accordingly, this  
association further highlights the importance of the interaction between genes and the environment in IBD pathogenesis.
PTK2B encodes protein tyrosine kinase 2β (also known as Pyk2), an important intracellular kinase for diverse signaling pathways, including mitogen-activated 
protein kinase (MAPK) and JNK signaling. Its functions include roles in monocyte migration and neutrophil degranulation.
NFATC1 encodes nuclear factor of activated T cells, cytoplasmic 1, an NFAT transcription factor that is specifically expressed upon activation of T and  
B cells following ligation of their respective receptors. This expression supports lymphocyte proliferation and inhibits activation-induced cell death, leading to 
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the concordant direction of effect at associated SNPs, there was high 
genetic correlation (rG) between the European and East Asian cohorts 
when considering the additive effects of all SNPs genotyped on 
the Immunochip19 (Crohn’s disease rG = 0.76 and ulcerative colitis 
rG = 0.79) (Supplementary Table 10). Given that rare SNPs (minor 
allele frequency (MAF) < 1%) are more likely to be specific to a 
particular population, these high rG values also support the notion that 
the majority of causal variants are common (MAF > 5%). Although 
the Indian and Iranian cohort sizes were small in comparison to the 
East Asian cohort, we observed similar trends for homogeneity of 
odds ratios at associated loci (Supplementary Figs. 9 and 10) and 
high genetic correlations with the European cohort (Supplementary 
Table 10). Together with the strong effect size correlations at known 
risk loci, these results indicate that the majority of IBD risk loci are 
shared across ancestral populations. Therefore, ancestry-matched 
groups of IBD cases and controls can be combined from divergent 
populations to amass the large sample sizes needed to detect further 
disease-associated loci.
Not all IBD risk loci are shared across populations, as evidence 
by rG being significantly less than 1 (P < 8.2 × 10−4) for all pair-
wise population comparisons. In most cases, apparent differences 
in genetic risk were explained by different allele frequencies across 
populations. For instance, consistent with previous genetic studies of 
Crohn’s disease in East Asians2, the three coding variants in NOD2 
(encoding nucleotide-binding oligomerization domain–containing 
protein 2) that had a large effect on IBD risk in Europeans (odds 
ratio (OR) = 2.13–3.03) had a risk allele frequency (RAF) of 0 in East 
Asians. Beyond these three coding variants, there is also evidence 
of at least four additional low-frequency independent NOD2 vari-
ants on the Immunochip that are associated with Crohn’s disease in 
Europeans (H.H., unpublished data). In the East Asian cohort, two of 
these variants had a RAF of 0, whereas we were not powered to detect 
association at the other two variants because we observed fewer than 
four copies of the risk allele (MAF < 0.0004). Furthermore, no SNP 
within NOD2 achieved even suggestive evidence of association in the 
East Asian cohort (all P > 7.18 × 10−4). Larger sample sizes and more 
complete ascertainment of variants (particularly in non-European 
cohorts) will be required to better assess the genetic architecture 
of NOD2 across divergent populations. Similarly, at the IL23R gene 
(encoding IL-23 receptor), previous studies have shown that there is 
substantial genetic heterogeneity between European and East Asian 
individuals in IBD risk2. In line with these observations, the IL23R 
SNP with the largest effect on risk of Crohn’s disease and ulcerative 
colitis in Europeans (rs80174646) had a RAF of 1 in East Asians, 
and secondary IL23R variants observed in Europeans were also not 
significantly associated with disease in the East Asian population 
(rs6588248, P = 0.65; rs7517847, P = 0.04). These two secondary vari-
ants are common in East Asians (rs6588248, MAF = 0.39; rs7517847, 
MAF = 0.42), and, assuming the effect sizes observed in Europeans, we 
had 100% power to detect association with rs7517847 at P < 5 × 10−8 
but only 84% power to detect association with rs6588248 at P < 0.05. 
Therefore, wecannot rule out the possibility that rs6588248 is involved 
in Crohn’s disease susceptibility in East Asians. Both variants showed 
significant heterogeneity of effect between the European and East 
Asian Crohn’s disease cohorts (P < 2.44 × 10−4). However, IL23R 
clearly has a role in IBD in the East Asian population, as evidenced 
by the association at rs76418789 with both Crohn’s disease and 
ulcerative colitis in East Asians (IBD P = 1.83 × 10−13). The same 
variant was previously implicated in a GWAS of Crohn’s disease in 
Koreans (Supplementary Table 5) (ref. 4). This variant, which has 
a much lower allele frequency in Europeans (MAF = 0.004) than 
East Asians (MAF = 0.07), demonstrated suggestive evidence of 
association with IBD in Europeans (P = 3.99 × 10−6; OR = 0.66) and 
became genome-wide significant (P = 2.31 × 10−10; OR = 0.53) after 
conditioning on the three known European risk variants (rs11209026, 
rs6588248 and rs7517847).
We were well powered to detect genetic heterogeneity between 
our East Asian and European cohorts at several alleles of large effect 
in Europeans (Fig. 2 and Supplementary Fig. 10). For example, at 
ATG16L1, the reported Crohn’s disease risk variant in Europeans 
(rs12994997) had a RAF of 0.53 and an OR of 1.27. The variant showed 
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Figure 1 Comparison of odds ratios for Crohn’s disease and ulcerative colitis risk variants in Europeans and East Asians. (a,b) For each SNP, odds ratios 
(on a log scale) were estimated within each population for Crohn’s disease (a) and ulcerative colitis (b). The color of each point denotes the association 
P value for that phenotype in East Asians. The red line denotes the best-fitting least-squares regression line, weighted by the inverse of the variance of 
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least in part by a significant difference in allele frequency (RAF = 0.24 
in East Asians; FST = 0.15). However, assuming the effect size at this 
SNP in the East Asian cohort was equal to that seen in the European 
cohort, we would still have more than 80% power to detect suggestive 
evidence of association (P < 5 × 10−5). In addition to differences in 
allele frequency, we also observed evidence of heterogeneity of odds 
at this SNP (East Asian OR = 1.06; P = 8.45 × 10−4). The previously 
reported lead SNP at the IRGM locus in Europeans also showed only 
nominally significant evidence of association with Crohn’s disease 
in East Asians (rs11741861: European P = 5.89 × 10−44, East Asian 
P = 2.62 × 10−3) as well as evidence of heterogeneity of effect (European 
OR = 1.33 versus East Asian OR = 1.13; heterogeneity P = 1.20 × 10−3). 
However, not all loci demonstrating significant heterogeneity of odds 
had lower effect sizes in the non-European cohort: two of the three 
independent signals at TNFSF15-TNFSF8 had much larger effects 
on IBD risk in East Asians (rs4246905: European OR = 1.15 and East 
Asian OR = 1.75; rs13300483: European OR = 1.14 and East Asian 
OR = 1.70), despite similar allele frequencies in the two populations. 
The third European risk variant was not significantly associated in 
East Asians (rs11554257: P = 0.21), although this might reflect a lack 
of power (76% power to detect this variant at P < 0.05 when assuming 
an identical odds ratio).
Although the incidence of IBD is rising in developing countries, 
comparable data on the clinical phenotype of disease in European and 
non-European populations are limited. We collected subphenotype 
data on 4,686 patients with IBD from East Asia, India and Iran and 
compared these data with available clinical phenotypes for 35,128 
Europeans. Given that the current cohort is the largest available for 
clinical comparisons of IBD in Europeans and non-Europeans, we 
performed basic comparative statistical analyses. Overall, our data 
showed some demographic differences between the European and 
non-European populations, with male predominance in Crohn’s 
disease (67% of non-European patients with Crohn’s disease were 
male in comparison to 45% of European patients; P = 7.09 × 10−78). 
Furthermore, we observed more stricturing behavior (P = 2.02 × 10−33) 
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Figure 2 Comparison of variance explained per risk variant for Crohn’s disease and ulcerative colitis between East Asians and Europeans. (a,b) Each 
box represents an independently associated SNP for Crohn’s disease (a) and ulcerative colitis (b). The size of each box is proportional to the amount 
of variance in disease liability explained by that variant. Only SNPs with association P < 0.01 are included in the East Asian panel. The color of each 
box denotes whether any difference in variance explained is due to differences in allele frequency (FST > 0.1/monomorphic in East Asians), significant 
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disease (P = 4.28 × 10−32) in the non-European population. In ulcera-
tive colitis, there was a lower rate of extensive colitis reported in the 
non-European population (P = 1.52 × 10−34), which was also reflected in 
a lower rate of colectomy (P = 1.23 × 10−69) (Supplementary Table 11). 
Although these data have been collected retrospectively, the current 
findings are in line with previously reported prospectively collected 
clinical findings in incident cases of IBD in non-Europeans2.
DISCUSSION
We identified 38 additional IBD susceptibility loci by adding an extra 
11,535 individuals of European descent and 9,846 individuals of non-
European descent to our previously reported European-only cohort 
of 75,105 samples. Given that trans-ancestry association studies prin-
cipally identify risk loci shared across populations, we would expect 
to identify a similar number of associated loci had all the individuals 
in this study been of the same ancestry. Our analyses suggest that 
significant differences in effect size are minimal at all but a handful 
of associated loci, further indicating that trans-ancestry association 
studies represent a powerful means of identifying new loci in com-
plex diseases such as IBD. Furthermore, the nearly complete sharing 
of genetic risk among individuals of diverse ancestry has important 
consequences for association studies and disease risk prediction in 
non-European populations. First, a significant association in one 
population makes the locus in question a very strong candidate for 
involvement in IBD risk worldwide. Second, our data suggest that 
odds ratios estimated from a very large association study are likely to 
better represent the effect size of the associated variants in a second, 
ancestrally diverse population than those estimated from a substan-
tially smaller study in the second population itself (because of the 
larger sampling variance in the second study). Finally, because rare 
alleles are more likely than common variants to be specific to a partic-
ular population, the substantial number of IBD risk loci shared across 
ancestral populations implies that the underlying causal variants 
at these loci are common. This adds further weight to the grow-
ing number of arguments against the ‘synthetic association’ model 
explaining a large proportion of GWAS loci20–22.
Although the majority of risk-associated loci are shared across 
populations, we were able to detect a handful of loci demonstrating 
heterogeneity of effect between populations. Major European risk 
variants in NOD2 and IL23R are not present in individuals of East 
Asian ancestry. The relatively small sample size of the non-European 
cohorts and the fact that Immunochip SNP selection was only based 
on resequencing data from individuals of European ancestry hinder 
our ability to identify association with sites that are monomorphic in 
Europeans but polymorphic in non-Europeans. Targeted resequenc-
ing efforts in large numbers of non-European IBD cases and controls, 
similar to those undertaken in European cohorts, may identify such 
associations and thus provide further insight into the genetic architec-
ture of IBD23,24. The much smaller number of individuals in the non-
European cohorts also reduces power to detect heterogeneity of effect 
versus the European cohort, and we therefore may be overestimating 
the degree of sharing between the various ancestry groups.
In addition to allele frequencies differing between ancestral popula-
tions, patterns of LD can also vary greatly; such differences further 
complicate comparisons of genetic architecture for complex disease 
across diverse populations. For example, we observed significant 
heterogeneity of odds at the TNFSF15-TNFSF8 and ATG16L1 loci, 
potentially suggesting that gene-environment interactions increase 
the variance explained by these associations in either European 
(ATG16L1) or non-European (TNFSF15-TNFSF8) populations. 
Although this hypothesis is attractive, the heterogeneity in effect 
sizes could also be underpinned by differential tagging of untyped 
causal variants at these loci in one or both populations. Although the 
Immunochip provides dense coverage of 186 previously associated 
loci, SNP selection was based on low-coverage sequence data from 
a pilot release of the 1000 Genomes Project. Approximately 240,000 
SNPs were selected for inclusion, with an assay design success rate 
of approximately 80%. Therefore, it is possible that causal variants 
could remain untyped, even within the dense fine-mapping regions 
of the Immunochip, and the chances of this occurring are greater still 
in populations of non-European ancestry. Until the causal variants 
that underlie these associated loci have been identified (or all SNPs 
within these loci are included in the association tests), we cannot rule 
out the possibility that differential tagging of untyped causal variants 
is driving the observed heterogeneity in effects.
In summary, we have performed the first trans-ancestry associa-
tion study of IBD and identified 38 risk loci, increasing the number of 
known IBD risk loci to 200. Together, these loci explain 13.1% and 8.2% 
of the variance in disease liability for Crohn’s disease and ulcerative 
colitis, respectively. The majority of these loci are shared across 
diverse ancestry groups, with only a handful demonstrating popula-
tion-specific effects driven by heterogeneity in RAF (for example, 
NOD2) or effect size (for example, TNFSF15-TNFSF8). Concordance 
in direction of effect is significantly enriched among SNPs demon-
strating only suggestive evidence of association, indicating that larger 
trans-ancestry association studies may represent a powerful means of 
identifying more risk loci for IBD. By leveraging imputation based on 
tens of thousands of reference haplotypes or directly sequencing large 
numbers of cases and controls, these studies will more thoroughly 
survey causal variants and thus have increased ability to model the 
genetic architecture of IBD across diverse ancestral populations.
URLs. National Human Genome Research Institute (NHGRI) 




Methods and any associated references are available in the online 
version of the paper.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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Ethical approval. The recruitment of study subjects was approved by the eth-
ics committees or institutional review boards of all individual participating 
centers or countries. Written informed consent was obtained from all study 
participants.
GWAS cohort, quality control and analysis. Cohorts and quality control. The 
GWAS cohorts and quality control are described in detail in Jostins et al.6. 
Briefly, seven Crohn’s disease and eight ulcerative colitis collections with 
genome-wide SNP data were combined. Samples were genotyped on a com-
bination of the Affymetrix GeneChip Human Mapping 500K, Affymetrix 
Genome-Wide Human SNP Array 6.0, Illumina HumanHap300 BeadChip 
and Illumina HumanHap550 BeadChip arrays. After SNP and sample quality 
control, the Crohn’s disease data consisted of 5,956 cases and 14,927 controls, 
the ulcerative colitis data consisted of 6,968 cases and 20,464 controls, and 
the data for Crohn’s disease and ulcerative colitis combined (IBD) consisted 
of 12,882 cases and 21,770 controls. The number of SNPs per collection varied 
between 290,000 and 780,000.
Imputation. Genotype imputation was performed using the prephasing/
imputation stepwise approach implemented in IMPUTE2/SHAPEIT (chunk 
size of 3 Mb and default parameters)37,38. The imputation reference set con-
sisted of 2,186 phased haplotypes from the full 1000 Genomes Project data set 
(August 2012, 30,069,288 variants, release v3.macGT1).
Association analysis. Genome-wide association analyses was carried out for 
Crohn’s disease, ulcerative colitis and IBD (the Crohn’s disease and ulcerative 
colitis cases combined). After applying filters requiring MAF > 1% and imputa-
tion INFO score > 0.6 to all imputed variants, around 9 million variants were 
found to be suitable for association analysis. Association tests were carried 
out in PLINK, using the post-imputation genotype dosage data and using 10, 
7 and 15 principal components for Crohn’s disease, ulcerative colitis and IBD, 
respectively, as covariates, chosen from the first 20 principal components. 
The Crohn’s disease, ulcerative colitis and IBD scans had genomic inflation 
(λGC) values of 1.129, 1.114 and 1.160, respectively. Accounting for inflation 
due to sample size and polygenic effects, these Crohn’s disease, ulcerative 
colitis and IBD λΓ values are equivalent to λGC 1,000 (the inflation factor from 
a sample size of 1,000 cases and 1,000 controls)39 values of 1.015, 1.011 and 
1.010, respectively.
Immunochip cohort, quality control and analysis. Description of the 
Immunochip. The Immunochip is an Illumina Infinium microarray compris-
ing 196,524 SNPs and small indel markers selected on the basis of results from 
GWASs of 12 different immune-mediated diseases. The Immunochip enables 
replication of all nominally associated SNPs (P < 0.001) from the index GWAS 
scans and fine mapping of 186 loci associated at genome-wide significance with 
at least 1 of the 12 index immune-mediated diseases. Within fine-mapping 
regions, SNPs from the 1000 Genomes Project pilot Phase 1 (European 
cohorts), plus selected autoimmune disease resequencing efforts, were selected 
for inclusion (with a design success rate of around 80%). The chip also con-
tains around 3,000 SNPs added as part of the Wellcome Trust Case Control 
Consortium 2 (WTCCC2) project replication phase. These SNPs are useful 
for quality control purposes because they have not previously been associated 
with immune-mediated diseases (‘null’ SNPs).
Cohorts of European ancestry. Recruitment of patients and matched controls 
genotyped with the Immunochip was performed in 15 countries in Europe, 
North America and Oceania (Table 1). Diagnosis of IBD was based on accepted 
radiological, endoscopic and histopathological evaluation. All included cases 
fulfilled clinical criteria for IBD. Genotyping was performed across 36 batches 
and included a total of 19,802 Crohn’s disease cases, 14,864 ulcerative coli-
tis cases and 34,872 population controls. The Immunochip cohort included 
3,424 Crohn’s disease cases, 3,189 ulcerative colitis cases and 7,379 population 
controls present in the GWAS cohort. The overlapping Immunochip samples 
were excluded from the trans-ancestry association analysis but included in 
the modeling of European versus non-European IBD because this was based 
solely on Immunochip data.
Cohorts of East Asian, Indian and Iranian ancestry. East Asian patients with 
IBD and controls were recruited from the following countries: Japan (Institute 
of Medical Science, University of Tokyo, RIKEN Yokohama Institute and Japan 
Biobank), Korea (Yonsei University College of Medicine and Asan Medical 
Centre, Seoul) and Hong Kong (Chinese University of Hong Kong). Indian 
IBD cases and controls were recruited from Dayanand Medical College and 
Hospital, Ludhiana, and the University of Delhi South Campus. Iranian cases 
and controls were recruited from the Tehran University of Medical Sciences. 
Samples recruited as part of a European cohort but that clustered with a non-
European cohort in principal-component analysis were reassigned to the non-
European cohort. In total, 6,598 East Asian, 3,088 Indian and 1,393 Iranian 
individuals were genotyped on the Immunochip (Table 1, Supplementary 
Figs. 1 and 2, and Supplementary Table 12).
Phenotype data. Detailed phenotype data (including sex, ancestry, age of 
disease onset, smoking status, family history, extraintestinal manifestations 
and surgery) were available for 47,799 European IBD cases and 3,986 non-
European IBD cases (Supplementary Table 11). Disease location and behavior 
were assessed with the Montreal classification. Clinical demographics and 
disease phenotype were compared in the European and non-European cohorts 
using χ2 analysis (SPSS 20).
Genotyping and calling. The Immunochip samples were genotyped in 36 
batches. Normalized intensities for all samples were centrally called using 
the optiCall clustering program40 with Hardy-Weinberg equilibrium blank-
ing disabled and the no-call cutoff set to 0.7. Before calling all data, we first 
established the optimal composition of sample sets. Calling per genotyping 
batch turned out to give the most reliable genotype clustering (in comparison 
to calling individual ancestral populations separately within each genotyping 
batch, calling all individuals per ancestry group together or calling all avail-
able data together).
Quality control. Quality control was performed separately in each popula-
tion (East Asian, Iranian, Indian and European) using PLINK41. Individuals 
were assigned to populations on the basis of principal-component analysis. 
This analysis was performed using EIGENSTRAT42 on a set of 15,552 
Immunochip SNPs that had pairwise r2 < 0.2 and MAF > 0.05 and were present 
in 1000 Genomes Project Phase 2 data. The first two principal components 
were estimated for the 1000 Genomes Project individuals and projected onto 
all Immunochip cases and controls. As expected, a clear separation between 
the different populations was seen (Supplementary Fig. 3). Samples were 
assigned to the population with which they clustered, and those that did not 
cluster with any of the reported populations were removed.
Marker quality control. SNPs were removed if they (i) were not on auto-
somes; (ii) had a call rate lower than 98% across all genotyping batches in the 
population and/or lower than 90% in one of the genotyping batches; (iii) were 
not present in 1000 Genomes Project Phase 1 data; (iv) failed Hardy-Weinberg 
equilibrium (FDR < 1 × 10−5 across all samples or within each genotyping 
batch); (v) had heterogeneous allele frequencies between the different genotyp-
ing batches within one population (FDR < 1 × 10−5; in genotyping batches with 
more than 100 samples); (vi) had different missing genotype rates for cases 
and controls (P < 1 × 10−5); and (vii) were monomorphic in the population. 
After marker quality control, 125,141 SNPs remained in the East Asian data 
set, 145,857 SNPs remained in the Indian data set, 152,232 SNPs remained in 
the Iranian data set and 144,245 SNPs remained in the European data set.
Sample quality control. Samples with a low call rate (<98%) and samples 
with an outlying heterozygosity rate (FDR < 0.01) were removed. Identity 
by descent was calculated using an LD-pruned set of SNPs with MAF > 0.05. 
Sample pairs with identity by descent of >0.8 were considered duplicates, and 
pairs with identity by descent of >0.4 and <0.8 were considered related. For 
all duplicate and related pairs, the sample with the lowest genotype call rate 
was removed. After sample quality control, 6,543 (2,824 cases, 3,719 controls) 
East Asian samples, 2,413 (1,423 cases, 990 controls) Indian samples, 890 (548 
cases, 342 controls) Iranian samples and 65,642 (31,664 cases, 33,977 controls) 
European samples remained.
Per-population association analysis. Case-control association tests for 
Crohn’s disease, ulcerative colitis and IBD were performed in each ancestry 
group (European, East Asian, Indian and Iranian) using a linear mixed model 
as implemented in MMM9. A covariance genetic relatedness matrix, R, was 
included as a random-effects component in the model to account for popula-
tion stratification. To avoid biases in the estimation of R due to the design of 
the Immunochip, SNPs were first pruned for LD (pairwise r2 < 0.2). Of the 





























MAF < 10%. SNPs that showed modest association (P < 0.005) with IBD in a 
linear regression model fitting the first ten principal components as covari-
ates were also excluded. A total of ~14,000 SNPs were used to estimate R  
(the number varied between cohorts).
Genomic inflation factor. The Immunochip contains 3,120 SNPs that were 
part of a bipolar disease replication effort and other non-immune-related stud-
ies. After quality control, 2,544 of these SNPs were used as null markers to 
estimate the overall inflation of the distribution of association test statistics 
(λ). There was minimal inflation in the observed test statistics (λ < 1.06) from 
each cohort (Supplementary Fig. 4).
Heterogeneity of effect. We tested the heterogeneity of associations across 
the four ancestry groups using the Cochran’s Q test. The analysis was per-
formed in R with the metafor package, using the odds ratios and standard 
errors estimated from each ancestry group. The I2 statistic from the Q test 
quantifies heterogeneity and ranges from 0% to 100% (ref. 43), with a value 
of 75% or greater typically taken to indicate a high degree of heterogeneity44. 
We performed Bonferroni corrections of this threshold for the 234 independ-
ently associated SNPs and considered I2 > 85.7% (Q = 27.94 with 4 degrees of 
freedom) to indicate significant evidence of heterogeneity.
Power calculations. All power calculations were performed using the 
Genetic Power Calculator45, assuming a disease prevalence of 0.005 and 
log-additive risk.
Variance explained. The proportion of variance in disease liability explained 
by the associated variants was estimated assuming a disease prevalence of 0.005 
and log-additive risk46. Because odds ratios were more likely to be accurately 
estimated in the much larger European cohort, only European odds ratios and 
allele frequencies were used.
Trans-ancestry association analysis. MANTRA meta-analysis. The European, 
East Asian, Indian and Iranian per-population association summary statistics 
were combined into a trans-ancestry meta-analysis using MANTRA10. This 
method allows for differences in allelic effects arising from differences in LD 
between distant populations. MANTRA first assigns each population into clus-
ters using a Bayesian partition model of relatedness defined by the mean pair-
wise allele frequency differences between populations (FST), calculated using 
all SNPs on the Immunochip (Supplementary Fig. 11). As more closely related 
populations are more similar to each other with respect to allele frequency 
and LD with the causal variant, we would expect greater homogeneity in effect 
sizes. Conversely, more distant populations may exhibit greater heterogeneity 
in effect sizes. For each SNP, if there is no evidence of heterogeneity, all studies 
are placed in the same cluster, and the method is equivalent to a fixed-effects 
meta-analysis. Where the data are consistent with heterogeneity, the studies 
will be assigned to different clusters, with greater weight given to clusters 
that match the similarity in the ancestry from the prior model of relatedness. 
The strength of association is measured by a Bayes factor.
Manual inspection of associated SNPs. Evoker47 was used to manually inspect 
signal intensity plots for all non-HLA loci with association P < 1 × 10−7 (for 
MMM) or log10 (Bayes factor) > 6 (for MANTRA) in any of the three pheno-
types. At each locus (defined here as a 300-kb window centered on the most 
strongly associated SNP), the top ten SNPs as ranked by P value were selected 
for inspection. Every SNP was inspected by two different researchers. SNPs 
that were passed by both researchers were taken forward.
Locus definition. Genome-wide significant loci were defined by an LD win-
dow of r2 > 0.6 from the lead SNP in the region with per-population association 
P < 5 × 10−8 or log10 (Bayes factor) > 6. The threshold of log10 (Bayes factor) 
> 6 has been suggested to be a conservative threshold for declaring genome-
wide significance48. Regions less than 250 kb apart were merged into a single 
associated locus. All LD calculations were performed using the control samples 
in each population.
Crohn’s disease, ulcerative colitis and IBD likelihood modeling. Associated loci 
were classified according to their strength of association with Crohn’s disease, 
ulcerative colitis or both using a multinomial logistic regression likelihood-
modeling approach within the Europeans-only cohort6. Four multinomial 
logistic regression models with parameters βCrohn’s disease and βulcerative colitis  
were fitted with the following constraints: (1) Crohn’s disease–specific 
model: βulcerative colitis = 0 (1 degree of freedom), (2) ulcerative colitis–specific 
model: βCrohn’s disease = 0 (1 degree of freedom) and (3) IBD unsaturated model: 
βCrohn’s disease = βulcerative colitis = βIBD (1 degree of freedom). A fourth uncon-
strained model with 2 degrees of freedom was also estimated with βCrohn’s disease 
and βulcerative colitis both fitted by maximum likelihood. Log likelihoods were 
calculated for each model, and three likelihood-ratio tests were performed 
comparing models 1–3 against the unconstrained model. If the P values of all 
three tests were less than 0.05, the SNP was classified as associated with both 
Crohn’s disease and ulcerative colitis but with evidence of different effect sizes. 
Otherwise, of the three constrained models, the SNP was classified according 
to the model with the largest likelihood. If IBD unsaturated was the best- 
fitting model, the locus can be interpreted as being associated with both Crohn’s 
disease and ulcerative colitis but with no evidence of different effect sizes.
Locus annotations and candidate gene prioritization. Associations with 
other phenotypes. IBD risk loci were annotated with the National Human 
Genome Research Institute (NHGRI) GWAS Catalog accessed on 15 August 
2014. Newly identified IBD loci that overlapped with a GWAS locus (com-
prising 250 kb on either side of the reported SNP) for another phenotype 
were reported. Only SNPs with association P < 5 × 10−8 in the GWAS catalog 
were considered.
Nonsynonymous SNPs. Functional annotation was performed using func-
tionGVS (dbSNP Build 134). A variant was annotated as a coding SNP if it was 
classified as ‘missense’ or ‘nonsense’ or if it had an LD of r2 > 0.8 (in Europeans 
or East Asians) with a SNP with such a classification. The genes in which these 
missense variants lay were included as coding SNP–implicated genes.
Expression quantitative trait loci. We tested whether each of the IBD- 
associated variants showed an effect on the expression levels of genes (acting 
as cis eQTLs) in whole blood. For this analysis, we used gene expression and 
genotype data from the Fehrmann study (n = 1,240) and the EGCUT study 
(n = 891)49,50. Gene expression normalization was performed as described 
previously, correcting for up to 40 principal components14. eQTL effects were 
determined using Spearman’s rank correlation and subsequently underwent 
meta-analysis using a sample-weighted z-score method. SNPs (MAF > 5%, 
Hardy-Weinberg equilibrium P value > 0.001) were tested against probes 
within 250 kb of the SNP. Multiple-testing correction was performed by con-
trolling the FDR at 5%, using a null. For each significant IBD eQTL probe, 
we determined the variant having the largest eQTL effect size (within 250 kb 
of the probe). We then removed the effect of this top associated variant using 
linear regression and repeated the analysis on the IBD variant. This allowed 
us to determine whether the eQTL effect of the IBD variant was either the top 
eQTL effect in a locus or the IBD variant had an eQTL effect independent of 
the top effect in the locus.
GRAIL network analysis. GRAIL evaluates the degree of functional con-
nectivity of a gene based on the textual relationships among genes. To avoid 
publication biases from large-scale GWAS, we used all PubMed text before 
December 2006. We used the GRAIL web tool to perform this analysis and 
took the list of loci from Supplementary Table 9. As in the previous study, 
we removed associations in the MHC region and replaced regions with the 
four well-established genes (IL23R, ATG16L1, PTPN22 and NOD2) to reduce 
noise. Only genes with GRAIL P < 0.05 and edges with a score >0.5 were used 
in the connectivity map51.
Protein-protein interaction networks (DAPPLE). DAPPLE uses protein-pro-
tein physical interactions to evaluate the disease association of genes. Each 
gene is assigned an empirical P value on the basis of its enrichment in interac-
tions with other genes in the list. We used the DAPPLE web tool to perform 
this analysis and took the list of loci from Supplementary Table 9. As in the 
GRAIL analysis, we removed associations in the MHC region and used the 
four established genes instead of their regions. Genes with DAPPLE P < 0.05 
were reported52.
ENCODE regulatory features. The following regulatory features from the 
Encyclopedia of DNA Elements (ENCODE)53 were used to annotate IBD risk 
loci: DNase I hypersensitivity sites, transcription factor binding sites, histone 
modification sites and DNA polymerase binding sites. The cell types in which 
these features occur are also reported. Regulatory elements were extracted 
using the Variant Explorer tool.
Modeling European versus non-European IBD risk. Effect size and frequency 





























the likelihood modeling, we estimated correlation between the log(OR) values 
in European and non-European populations using a weighted linear regres-
sion with the inverse variance of the non-European log(OR) values as weights. 
For an associated SNP, differences in the effect size between two populations 
were tested using t tests for a significant difference in log(OR). FST values for a 
SNP between two populations were calculated using the Weir and Cockerham 
method on allele frequencies in control samples only54. The proportion of 
variance explained by each associated locus per population was calculated 
using a liability threshold model53 assuming a disease prevalence of 500 per 
100,000 and log-additive disease risk.
Genetic correlations. The proportion of genetic variation tagged by 
Immunochip SNPs that was shared by the European cohort and each non-
European cohort (rG) was estimated using the bivariate linear mixed-effects 
model implemented in GCTA19. The method was applied across Immunochip-
typed individuals for each European versus non-European pairwise compari-
son for Crohn’s disease and ulcerative colitis, with 20 principal components as 
covariates and assuming a disease prevalence of 0.005. To test whether rG was 
significantly different from 0 (or 1), rG was fixed at 0 (or 1) and a likelihood-
ratio test comparing this constrained model with the unconstrained model 
was applied. An rG of 0 means that no genetic variants are shared by the two 
populations, whereas a value of 1 means that all the genetic variance tagged in 
one population are shared with the other. In the European cohort, only 10,000 
cases and 10,000 controls (selected at random) were included because of com-
putation limitations, whereas all non-European samples were included.
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